AUTL News and Press, Autolus Therapeutics plc From 02/15/23

Summary Primary endpoint met with interim analysis released from phase 1b/2 FELIX study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia; 70% Overall Remission Rate achieved. Recently released positive interim analysis results with obe-ce...

Summary Today, we circle back on a small T cell therapeutic concern called Autolus Therapeutics plc for the first time since the first half of 2021. The company is advancing its pipeline, recently addressed its near-term funding needs and could have potentially key trial data out at mid...

LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company’s Board of Directors. The company’s non-executive Cha...

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CA...

Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia therapy Obe-cel: continues to show high level of sustained clinical activity in B-NHL patients ...

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering after the market closed on Thursday. Autolus said that it plans to offer 75 millio...

Autolus Therapeutics ( NASDAQ: AUTL ) shares sank 23.1% after-hours after the firm has priced its previously announced underwritten public offering of 75M American Depositary Shares representing 75M ordinary shares at a public offering price of $2.00/ADS, for total gross proceeds...

Autolus Therapeutics ( NASDAQ: AUTL ) on Thursday said it had commenced a public offering of its American depositary shares. U.S.-listed shares of AUTL fell 20.7% to $2.37 in aftermarket trading. The size of the proposed offering was yet to be determined. AUTL after ho...

Autolus Therapeutics ( NASDAQ: AUTL ) on Thursday said it would get $70M over two milestone payments from private investment platform Blackstone Life Sciences. AUTL and Blackstone in Nov. last year had entered into a collaboration and financing deal under which Blackstone agreed to gi...

Autolus Therapeutics ( NASDAQ: AUTL ) on Thursday said an interim analysis of a phase 2 study of its investigational CAR-T cell therapy obe-cel for the treatment of a type of blood cancer found that the trial had met its main goal. According to the interim analysis, obe-cel showed an ...